Abstract Aberrant expression of epigenetic regulators of gene expression contributes to initiation and progression of cancer. During recent years, considerable research efforts have focused on the role of histone acetyltransferases (HATs) and histone deacetylases (HDACs) in cancer cells, and the identification of pharmacologic agents that modulate gene expression via inhibition of HDACs. The following review highlights recent studies pertaining to HDAC expression in cancer cells, the plieotropic mechanisms by which HDAC inhibitors (HDACi) mediate antitumor activity, and the potential clinical implications of HDAC inhibition as a strategy for cancer therapy.
Histone Acetyltransferases and Histone Deacetylases
Acetylation of core histones is governed by opposing actions of a variety of histone acetyltransferases (HAT) and HDACs.
Histone acetylases mediate transfer of an acetyl group from acetyl-co-A to the q-amino site of lysine and are divided into two groups. Type A HATs are located in the nucleus, and acetylate nucleosomal histones as well as other chromatinassociated proteins; as such, these HATs directly modulate gene expression. In contrast, type B HATs are localized in the cytoplasm, and acetylate newly synthesized histones, thus facilitating their transport into the nucleus and subsequent association with newly synthesized DNA (4, 5) . Type A HATs typically are components of high-molecular complexes and comprise five families; GNAT, P300/CBP, MYST, nuclear receptor coactivators, and general transcription factors (4) . Some HATs, notably p300 and CBP, associate with a variety of transcriptional regulators including Rb and p53, and may function as tumor suppressors. In addition, HATs acetylate a variety of nonhistone proteins including p53, E2F1, Rb, p73, HDACs, and heat shock protein (Hsp) 90 (Table 1; refs. 6, 7).
HDACs are currently divided into four classes based on phylogenetic and functional criteria (reviewed in ref. 7) . Class I HDACs (1 -3, 8) , which range in size from f40 to 55 Kd, are structurally similar to yeast transcription factor, Rpd-3, and typically associate with multiprotein repressor complexes containing sin3, Co-REST, Mi2/NuRD, N-COR/SMRT, and EST1B (8) . HDACs 1, 2, and 3 are localized in the nucleus, and target multiple substrates including p53, myo-D, STAT-3, E2F1, Rel-A, and YY1 (9, 10) . HDAC 8 is localized in the nucleus as well as the cytoplasm; no substrates of this class I HDAC have been defined to date.
Class II HDACs (4 -7, 9, 10), which range in size from f70 to 130 Kd, are structurally similar to yeast HDA1 deacetylase and are subdivided into two classes. Class IIA HDACs (4, 5, 7, 9) contain large N-terminal domains that regulate DNA binding and interact in a phosphorylation-dependent manner with 14-3-3 proteins, which mediate movement of these HDACs between cytoplasm and nucleus in response to mitogenic signals (7) . Class IIB HDACs (6 and 10) are localized in the cytoplasm. HDAC 6 is unique in that it contains two deacetylase domains and a zinc finger region in the C-terminus. HDAC 10 is similar to HDAC 6, but contains an additional inactive domain (7, 10) .
In contrast to class I HDACs, class II HDACs exhibit familyrestricted interactions with a variety of proteins including ANKRA, RFXANK, estrogen receptor (ER), REA, HIF1a, Bcl-6, and Fox3P. These HDACs have a variety of nonhistone target substrates including GATA-1, GCMa, HP-1, and SMAD-7, as well as FLAG-1 and FLAG-2 (9, 10) . Relatively little information is available about binding partners for HDAC 6 and HDAC 10 (11, 12) . Notably, HDAC 6 has emerged as a major deacetylase of a-tubulin as well as Hsp90; as such, HDAC 6 mediates cell motility, and stability of oncoproteins such as EGFR, RAF1, and ABL, which are client proteins of Hsp90 (13) . Additionally, HDAC 6 can interact via its zinc finger with ubiquitin to modulate aggressesome function and autophagy (14) . Recent studies suggest that HDAC 10 may also function to modulate acetylation of Hsp90 (15) .
Class I and class II HDACs are zinc-dependent enzymes containing catalytic pockets that can be inhibited by zinc chelating compounds such as hydroxamic acid. HDAC 11, the only known class IV HDAC, exhibits conserved residues within the catalytic domain that are shared with class I and class II HDACs; binding partners and target substrates for this HDAC have not been defined to date (10, 16) . Class I, class II, and class IV HDACs are referred to as ''classical'' HDACs, and are targeted by HDACi currently in clinical development. In contrast, class III HDACs (sirtuins) are structurally similar to yeast SirT2, and require NAD+ as a cofactor for enzymatic activity (17) . Recent studies suggest that sirtuins are critical regulators of energy-dependent transcription. These latter HDACs, which are rapidly emerging as potential novel targets for cancer therapy, will not be further discussed here because of the limited clinical experience with sirtuins inhibitors. Several recent reviews have focused on the biochemistry and potential clinical significance of class III HDACs (18, 19) .
HDAC Activity in Normal and Malignant Tissues
Despite structural similarities, HDACs exhibit nonredundant functions during embryogenesis, and aberrant HDAC expression in cancers may be a manifestation of tissue-specific epigenetic reprogramming events (9, 10) . Knock-out of HDACs 1, 2, 3, or 7 results in embryonic lethality in mice owing to aberrant cell cycle regulation or abnormal blood vessel development; in contrast, mice lacking HDACs 4, 5, 6, or 9 are viable, yet exhibit markedly abnormal cardiovascular, bone, and muscle development (reviewed in ref. 10 ). The unique roles of individual HDACs regarding embryonic development and maintenance of organ function may account, in part, for activities and potential systemic toxicities of HDACi currently evaluated in clinical settings.
In light of the complex roles of HDACs during embryogenesis and their expression profiles in normal tissues, it is not surprising that the effects of targeted inhibition of HDACs in cancer cells seem tissue-dependent. For example, knock-down of HDAC 1 inhibits proliferation of cultured colon cancer cells, and induces apoptosis in osteosarcoma and breast cancer cells (20, 21) . Knock-down of HDAC 2 induces growth arrest in colon cancer cells, but has no such effects in osteosarcoma or breast cancer cells (20, 21) . However, inhibition of HDAC 2 down-regulates ER/PR expression, and potentiates tamoxifeninduced apoptosis in ER/PR positive breast cancer cells (22) . Knock-down of HDAC-2 enhances p53-dependent gene activation/repression, and inhibits proliferation of cultured breast cancer cells (23) . Knock-down of HDAC 8, which modulates telomerase function by inhibiting ubiquitin-mediated degradation of hEST1B (24) , inhibits proliferation of lung, colon, cervical carcinoma, and neuroblastoma cells, and induces apoptosis in cultured lymphoma/leukemia cells (25 -27) .
To date, targeted inhibition of class II HDACs has not been systematically examined. However, knock-down of HDAC 6 or HDAC 10 enhances acetylation of Hsp90 in various cancer cell lines, resulting in destabilization of client oncoproteins such as Bcr-Ab1, and VEGF-R (15, 12) .
Clinical Manifestation of HDAC Expression in Cancer
A number of studies have been done recently to examine expression and potential relevance of HDAC expression in cancer tissues. The majority of reports have focused on class I HDACs and suggest the clinical manifestations of aberrant HDAC expression may be histology dependent (28) . Nakagawa and colleagues (29) systematically examined expression levels of HDACs 1, 2, 3, and 8 in a variety of cultured cancer lines and a broad panel of primary human lung, esophageal, gastric, colon, pancreas, breast, ovary, and thyroid cancers. Seventy-five percent of esophageal, gastric, colon, and prostate cancers, as well as corresponding adjacent ''normal'' tissues exhibited ''high-level'' class I HDAC expression. Although HDAC expression in tumors often was not higher than corresponding normal tissues, 5% to 40% of these cancers exhibited HDAC over-expression; esophageal and prostate cancers tended to exhibit more consistent over-expression of class I HDACs. Additional studies suggest that high level HDAC 1 expression correlates with advanced stage of disease in lung cancer patients (30) , as well as aggressive tumor histology, advanced stage of disease, and poor prognosis in patients with pancreatic carcinoma (31) . In contrast, HDAC 1 expression in breast cancer is associated with estrogen receptor (ER)/progesterone (PR) expression, earlier stage of disease (T as well as N classifications), and improved patient survival (32, 33) .
In a large retrospective study, Weichert, and colleagues (34) observed simultaneous over-expression of HDACs 1, 2, and 3 in approximately 30% of 150 gastric cancers. An additional 30% of tumors exhibited very low or undetectable expression of these HDACs; global HDAC 1 over-expression in primary cancers correlated significantly with nodal metastases and diminished patient survival. In an additional study, high-level (26) . Relatively limited information is available about the frequency and clinical relevance of class II HDAC expression in human cancers. Over-expression of HDAC 4 has been observed in breast cancers, relative to renal, colorectal, or bladder cancers, whereas colon cancers seem to have relatively higher levels of HDACs 5 and 7 (28) . Decreased expression of several class II HDACs, particularly HDACs 5 and 10, seems to correlate with advanced stage of disease and diminished survival of lung cancer patients (37) . HDAC 6 expression correlates with advanced stage of disease in oropharyngeal cancers (38) . In contrast, HDAC 6 expression in breast cancers coincides with early stage tumors, ER/PR expression, response to tamoxifen, and in some cases, improved patient survival (39) .
Cytotoxic Effects of HDAC Inhibitors
During recent years, intense efforts have focused on the development of HDACi for cancer therapy. These initiatives have been prompted by considerable preclinical evidence of plieotropic cytotoxic effects of HDACi of diverse structural classes in cultured cancer cells and various human tumor xenografts ( Fig. 1) , as well as encouraging results of early phase trials in cancer patients.
Effects on gene expression. HDACi mediate complex effects on global gene expression by directly modulating chromatin structure via acetylation of core histones, as well as ''marking'' chromatin for subsequent recruitment of chromatin remodeling complexes (40) . Equally and perhaps more importantly, these agents influence gene expression via acetylation of numerous nonhistone proteins involved in signal transduction and transcription (Table 1 ) (6). In general, acetylation increases the negative charge of core histones, resulting in relaxation of chromatin structure; whereas chromatin decondensation often enhances gene expression, the net effect of histone acetylation on transcriptional activity of different genes is influenced by concomitant alterations in chromatin structure mediated by DNA as well as histone methylation, and the summation of activators and repressors recruited to the respective promoters (41, 42) . These issues account for the fact that only f10% of genes are modulated by HDACi, with approximately equal if not more numbers repressed as induced by these agents (reviewed in ref. 9 ). Gene expression profiles in cancer cells mediated by HDACi of diverse structural classes including sodium butyrate, vorinostat, MS-275, TSA, and FK228 are time and dose dependent; although many similarities have been observed about effects of various HDACi on gene expression, some profiles seem agent specific (43 -47) .
The majority of such micro-array studies pertain to analysis of gene expression in cultured cancer lines; limited information is available about gene expression alterations in primary tumors from patients receiving HDACi. In a recent clinical trial, long oligo array techniques were used to examine global gene expression profiles in laser-captured tumor cells from pre-and post-treatment biopsies from lung cancer patients receiving FK228 infusions. Pretreatment RNA was used as the reference for each respective post-treatment array. Considerable heterogeneity was detected in baseline as well as post-treatment gene expression profiles. Only 16 genes were induced twofold or more in one or more patients following FK228 treatment. In contrast, more than 1,000 genes were repressed twofold or more in one or more patients following FK228 infusion (48) . Results of these arrays were compared with a large, robust data set pertaining to gene expression profiles in laser captured lung cancer cells and adjacent histologically normal bronchial epithelia from patients undergoing potentially curative resections. Those genes that were induced or repressed twofold or more by FK228 seemed to be down-regulated or overexpressed, respectively, in the resected primary lung cancers relative to adjacent, histologically normal bronchial epithelial cells (Fig. 2) .
One of the genes consistently induced by HDACi in vitro and in vivo is p21, which is up-regulated via p53 dependent as well as p53 independent mechanisms (49 -51). Activation of p21 coincides with acetylation of histones H3 and H4, methylation of several histone sites within the p21 promoter, and alterations of multiprotein complexes that regulate p21 transcription. Vorinostat as well as TSA-mediated activation of p21 coincides with dissociation of HDAC 1 and c-myc, and recruitment of RNA polymerase II within the p21 promoter (52, 53) . Other genes, such as Aurora B, are directly down-regulated via HDACi mediated recruitment of repressor complexes (Fig. 3) (42) .
It is well established that HDACi enhance activation of aberrantly methylated tumor suppressor gene promoters in cancer cells by DNA demethylating agents such as 5-azacytidine (5-AC) and 5-aza-2 ¶deoxycytidine (DAC) (54, 55) . In addition, HDACi potentiate de novo induction of germ-cell restricted genes such as NY-ESO-1 and MAGE family members in cancer cells by DNA demethylating agents (56, 57) . Although these phenomena have been attributed to acetylation of core histones, more recent studies suggest that potentiation of 5-AC or DAC-mediated gene induction by HDACi may be more complex. For example, Xiong and colleagues (58) , observed that TSA decreases stability of DNMT3b mRNA, resulting in diminished de novo methylation activity in human endometrial cancer cells. You and colleagues (59) Modulation of cell cycle progression. Depending on exposure conditions, HDACi of various structural classes induce G1/S and/or G2/M arrest, and disrupt mitotic progression in normal as well as malignant cells. Cell cycle arrest mediated by HDACi coincides with decreased expression of cyclins A, B, D, and E, as well as their respective cyclin-dependent kinases, hypophosphorylation of Rb, and induction of p21 and p27 (63) .
Presently, the mechanisms contributing to aberrant mitotic progression in cancer cells following exposure to HDACi are less fully defined. HDAC 3 is critical for maintaining deacetylated histone tails that become phosphorylated by Aurora B as cells enter mitosis, and inactivation of HDAC 3 induces mitotic delay and apoptosis in murine embryonic fibroblasts (64, 65) . (9, 63) . Depending on exposure conditions, these agents mediate caspase-independent autophagy as well as caspasedependent apoptosis in cancer cells of diverse histologies.
Autophagy is a complex process by which proteins and organelles are sequestered in autophagosomes and subsequently degraded following fusion with lysosomes. Autophagy is induced by nuclear (but not cytoplasmic) p53 via up-regulation of damage-regulated autophagy modulator (DRAM), as well as p73 in response to cellular stress (71, 72) . Recent studies indicate that mTOR regulates autophagy by inhibiting p73-mediated activation of a variety of genes including ATG5, ATG7, and UVRAG (73, 74) , and that p53 can inhibit mTOR via activation of AMPK (73) .
Autophagy induced by HDACi seems related to inhibition of HDAC 1 as well as HDAC 6 (75, 76). Shao and colleagues (77) observed that sodium butyrate and vorinostat mediated autophagy as well as apoptosis in HeLa cells; constitutive overexpression of Bcl-Xl inhibited caspase activation but did not seem to diminish cell death mediated by these HDACi. Hrzenjak and colleagues (78) observed that vorinostat diminished mTOR expression and mediated caspase-independent cytotoxicity in endometrial sarcoma cells via autophagic mechanisms. Furthermore, Watanabe and colleagues (79) observed that FK228-mediated autophagy in rhabdomyosarcoma cells coincided with nuclear translocation of apoptosis-inducing factor (AIF); knockdown of AIF abrogated autophagy following FK228 exposure. Chloroquine, an inhibitor of autophagy, enhanced FK228-mediated apoptosis in these cells. Carew and colleagues (80) examined the relative contributions of autophagy and apoptosis on vorinostat-mediated cytotoxicity in cultured chronic myelogenous leukemia (CML) cells. Chloroquine exposure dramatically increased reactive oxygen species formation and enhanced vorinostat-mediated apoptosis in these cells. The relative contributions of autophagy and apoptosis with regard to tumor regressions in clinical settings have yet to be fully elucidated. Of particular concern are observations that depending on tissue histology and/or context, autophagy may be cytoprotective (81) . For example, autophagy enhances anti-estrogen resistance in cultured breast cancer cells (82) , and protects cancer cells from hypoxia (83) . Cancer cells exhibit a variety of defects in caspase-mediated apoptotic pathways due to up-regulation of decoy receptors such as TRAIL-R3 and TRAIL-R4 that inhibit activation of death receptors by ligands such as TNF or TRAIL, as well as aberrant expression of anti-apoptotic proteins including Bcl-2, Bcl-xl, and XIAP family members, which inhibit caspase activation (9, 63) . HDACi including TSA, FK228, vorinostat, and panobinostat, decrease expression of Bcl-2, Bcl-xl, and XIAP, and enhance expression of pro-apoptotic proteins such as BAX and BAK, thereby enhancing TRAIL-mediated cytotoxicity in a variety of cancer cells via amplification of intrinsic as well as extrinsic apoptotic pathways (84, 85) . Agents such as flavopiridol that potentiate mitochondrial injury enhance apoptosis mediated by HDACi in cancer cells (86) . In addition, HDAC inhibitors augment apoptosis mediated by a variety of conventional chemotherapeutic agents by up-regulating death receptor 5 or other components of apoptotic pathways such as AIF, thereby enhancing caspase activation (87, 88) . Recently, Xu and colleagues (89) observed that MS275 as well as vorinostat induce TRAIL expression without altering DR4 or DR5 levels in breast cancer cells; HDACi induction of TRAIL by was mediated via SP1, and markedly enhanced adriamycin cytotoxicity in these cells.
Additional studies have examined the effects of HDACi on nuclear receptor signaling in cancer cells; results have varied depending on agents and exposure conditions, and hormone receptor status of cells used for these experiments (90) . For example, TSA potentiates derepression of ER-a mediated by DNA demethylating agents, and enhances response to tamoxifen in ER-negative breast cancer cells (91) ; TSA, as well as vorinostat, and valproic acid alone induce only modest upregulation of ER-a in these breast cancer cells. Jang and colleagues (92) observed that TSA markedly induced ER-h but not ER-a expression, and enhanced nuclear transport of ER-h, resulting in activation of ER target genes and increased tamoxifen sensitivity in ER negative cells. Fiskus and colleagues (93) observed that LAQ824, vorinostat, and panobinostat depleted ER-a via acetylation of Hsp90, thereby diminishing response to E2, and enhancing tamoxifen sensitivity in ERpositive breast cancer cells. Bicaku and colleagues (22) Fig. 3 . Modulation of p21and Aurora B expression in lung cancer cells following FK228 exposure. Calu-6 lung cancer cells were transiently transfected with p21or Aurora B luciferase promoter-reporter constructs. Twenty-four hours later, cells were exposed to FK228 (25 ng/ml). FK228 increased p21reporter activity, while diminishing Aurora B promoter-reporter activity in a time-dependent manner. Full details and additional experiments contained in ref. (42 (94) . TSA, vorinostat, and MS-275 inhibit expression of TMPRSS2-ERG fusion transcripts, and enhance apoptosis mediated by flutamide in androgen responsive prostate cancer cells in part by inhibiting translocation of AR from cytoplasm to the nucleus (95); in contrast, HDACi do not potentiate androgen blockade in AR-negative prostate cancer cells (96) . Welsbie and colleagues (97) comprehensively examined the mechanisms underlying the synergistic cytotoxic activity of AR blockade and HDAC inhibition in prostate cancer cells. Vorinostat and panobinostat inhibited AR-mediated activation of downstream target genes including TMPRSS2. Knock-down of HDAC 1 or HDAC 3 suppressed expression of androgen regulated genes and mimicked the effects of HDACi exposure in these cancer cells. Interestingly, inhibition of AR signaling by HDACi was independent of AR protein depletion. Additional experiments indicated that HDACi prevent assembly of co-activator/RNA pol II complexes after AR binds to enhancer elements of target genes.
A variety of studies have been done to examine the effects of HDACi on retinoic acid (RA) signaling in cancer cells (98) . Elegant functional genetic screening experiments revealed that apoptosis of p53-deficient murine embryonic fibroblasts expressing oncogenic ras exposed to PXD101, vorinostat, MS-275, sodium butyrate, and spiruchostatin A could be inhibited by constitutive expression of RARa or the preferentially expressed antigen of melanoma (PRAME), which represses RA signaling (99, 100) . The anti-apoptotic effects of RARa and PRAME did not seem attributable to modulation of histone acetylation. Additional studies have shown that combined valproic acid/RA or MS-275/RA regimens enhance apoptosis and decrease in vivo growth of neuroblastoma and renal carcinoma cells (101, 102) .
Effects on antitumor immunity. HDACi can potentially modulate antitumor immunity via numerous mechanisms including up-regulation of tumor antigens, enhancement of cellular immune recognition, and lysis of tumor targets by T cells and NK cells, and alteration of T-cell subsets as well as inflammatory cytokine profiles. FK228 as well as TSA enhance deoxyazacytidine-mediated activation of genes encoding cancer testis antigens such as NY-ESO-1 and MAGE family members, and augment NY-ESO-1 and MAGE expression in cancer cells exhibiting derepression of these germ-cell restricted genes; upregulation of antigen expression facilitates recognition of cancer cells by cytolyic T cells in vitro (103, 104) . Whereas HDACi such as TSA and FK228 enhance HLA expression (105) , exposure to these agents does not seem to restore antigen presentation in cancer cells deficient in antigen processing (103, 104) .
Several recent studies indicate that HDACi can modulate TH1/TH2 effector function (106) , and enhance the activity of Foxp3-positive regulatory T cells, which contribute to immune tolerance in cancer patients (107) . Furthermore, TSA abrogates interferon-gamma (IFN-g)-mediated inhibition of TNF-ainduced activation of inflammatory cytokine genes such as IL-6 and IL-8, which enhance metastatic potential of cancer cells (108, 109) . On the other hand, FK228 enhances NK cellmediated lysis of tumor cells of various histologies by up-regulating DR5 (TRAIL-R2) expression without altering expression of MHC-class I, DR-4 (TRAIL-R1), MIC A/B, or FAS (CD95) on tumor cells (110) . Consistent with these findings, Deirmayr and colleagues (111) observed that valproic acid enhances expression of NKG2D ligands on AML cells, thereby enhancing their susceptibility to NK cell-mediated lysis.
Sensitivity and mechanisms of resistance. Whereas HDACi induce cell cycle arrest in normal as well as nontransformed cells, the proapoptotic effects of these agents are observed primarily in cancer cells. Preferential tumoricidal activity mediated by HDACi seems related, at least in part, to differential responses of transformed and normal cells to oxidative stress. HDACi such as vorinostat decrease expression of thioreduxin (TRX) in transformed but not normal cells. TRX is a scavenger of reactive oxygen species (ROS), and a hydrogen donor for numerous proteins involved in DNA synthesis and transcription. In addition, TRX inhibits apoptosis signaling regulating kinase-1 (ASK-1). Vorinostat also increases expression of TRX binding protein, an inhibitor of TRX, thereby increasing expression of ASK-1. The net result is an accumulation of ROS, which triggers apoptosis/autophagy in cancer cells (112) .
Generation of ROS cannot fully account for sensitivity of cancer cells to HDACi. Increasing evidence indicates that even within given histologies, cancer lines or xenografts exhibit differential sensitivities to these agents. Several studies have been done recently to define gene expression profiles that correlate with response to HDACi in cancer cells. Susakawa and colleagues (113) identified a 76-gene expression signature that coincided with sensitivity of human tumor xenografts to FK228. Miyanaga and colleagues (114) identified a nine-gene expression signature that correlated with response of cultured lung cancer cells to TSA and vorinostat; modulation of three of these genes (NOG1, SEC23A: up-regulated; PSNE2: down-regulated) markedly correlated with sensitivity to these HDACi. More recently, Dejligbjerg and colleagues (115) observed that modulation four genes (ODC1, SKI, STAT1, TYMS) correlated with belinostat sensitivity in a broad panel of cultured cell lines. Dokamanovic and colleagues (115) An important issue about these studies is that HDACi sensitivity often was determined by proliferation rather than cytoxicity assays. Diminished proliferation in response to HDACi seems related, at least in part, to induction of p21, which may be cytoprotective in cancer cells exposed to chemotherapeutic agents and HDACi. Indeed, abrogation of p21 expression by agents such as flavopiridol, markedly enhances apoptosis mediated by HDACi in cultured cancer cells (117) . Furthermore, HDACi increase expression of nuclear factor nB (NFnB), which mediates a variety of prosurvival pathways in cancer cells (118) ; the relevance of NFnB activation regarding sensitivity of cancer cells to these agents is highlighted by the fact that parthenolide, which inhibits NFnB function, as well as proteosome inhibitors such as bortezamib, which prevent degradation of InB, markedly enhance cytotoxicity of TSA, vorinostat, valproic acid, and FK228 in cancer cells (119 -121) .
Recently, Fantin and colleagues (122) observed that activation of signal transducer and activation of transcription (STAT)-1,-3, and -5 correlated with vorinostat resistance in cultured lymphoma cells. Janus-activated kinase inhibition enhanced vorinostat-mediated cytotoxicity in these cells. Subsequent studies revealed that nuclear accumulation of STAT1 and increased levels of nuclear phospho-STAT3 in skin biopsies correlated with lack of response to vorinostat in patients with cutaneous T-cell lymphoma.
Observations that HDACi modulate apoptosis thresholds in cancer cells have prompted considerable interest in utilizing these agents to potentiate the effects of standard chemotherapeutic regimens or radiation therapy in clinical settings (123 -125) . However, HDACi may induce resistance that may be clinically relevant. For instance, FK228 is a substrate for P-glycoprotein (Pgp) and multidrug resistance-associated protein-1 (MRP1); up-regulation of Pgp seems to be a major mechanism of resistance to FK228 as well as apicidin in cultured cancer cells (126, 127) . Robey and colleagues (128) observed an eightfold increase in expression of MDR-1, which encodes Pgp, in circulating tumor cells from patients with hematologic malignancies receiving FK228. Additional studies have shown that FK228 induces expression of ABCG2; chromatin alterations within the ABCG2 promoter induced by FK228 are similar to those observed in drug-resistant cells (129) .
To date, the mechanisms mediating resistance to other HDAC inhibitors in cancer cells have not been fully defined. Vorinostat and valproic acid-induced resistance seems irreversible and unrelated to MDR-1 expression, and does not seem to alter sensitivity of cultured colon cancer cells to standard chemotherapeutic agents (130) . Fiskus and colleagues (131) observed that HL-60 cells selected for resistance to vorinostat, sodium butyrate, LAQ824, and panobinosat exhibited increased expression of HDACs 1, 2, and 4, yet lacked expression of HDAC 6. HL-60 cells resistant to HDACi were also resistant to etoposide, cytarabine, and TRAIL, and exhibited increased proliferation in vitro and in vivo, suggesting that HDACi exposure may select for outgrowth of cancer cells with a more aggressive phenotype.
Conclusions and Future Directions
HDACi have emerged as major pharmacologic agents for cancer therapy. In all likelihood, these agents will be used in combination with standard treatment regimens. Efforts to further develop these agents should be focused on thorough evaluation of HDAC expression in different human cancers, comprehensive analysis of the mechanisms of action of various classes of HDACi in vitro using array-based profiling techniques, and validation of recently identified prognosticators of response in clinical settings.
Synthesis of HDACi that selectively target HDACs relevant to cancer initiation/progression may enhance the antitumor effects while decreasing systemic toxicities of HDAC inhibition in cancer patients. For example, HDAC 6 enhances oncogenic transformation (132) , and modulates epithelial-mesenchymal transition in cancer cells (11) ; as such, selective inhibitors of HDAC 6 may prove highly effective for cancer therapy. As HDAC inhibitors are further evaluated in cancer patients, it will be important for investigators to remain cognizant of the potential immunosuppressive effects of these agents, given their ability to perturb T-cell function and alter expression of inflammatory cytokines mediating innate antiviral and antitumor immunity (106, 133 -135) .
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